Gastrinoma (DBCOND0000822)
Identifiers
- Synonyms
- Gastrinoma (disorder) / Gastrinoma (morphologic abnormality)
Associated Data
- Indicated Drugs and Targets
Drug Description Targets Pancrelipase A purified form of porcine pancreatic lipase, amylase, and protease enzymes used to treat malabsorption associated with pancreatic insufficiency resulting from cystic fibrosis and pancreatitis.- Dietary fattarget
- Dietary proteintarget
- Dietary starchtarget
Secretin human A secretin hormone used to stimulate pancreatic or gastric secretions to diagnose exocrine pancreas dysfunction, gastrinoma, and abnormalities in the bile and pancreatic ducts.- Secretin receptortarget
- Clinical Trials
Identifier Title Drug(s) Purpose Phase Status NCT00084461 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors treatment 2 terminated NCT02273752 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer treatment 2 terminated NCT02259725 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors treatment 2 completed NCT02108782 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors treatment 2 withdrawn NCT00001240 Evaluating Patients With Abnormal Levels of Gastric Acid No drug interventions Not Available Not Available completed NCT00655655 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors treatment 1 completed NCT03583528 DOTATOC PET/CT for Imaging NET Patients No drug interventions Not Available Not Available recruiting NCT00131911 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors treatment 2 completed NCT01824875 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors treatment 2 active_not_recruiting NCT02031536 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery treatment 2 terminated NCT00075439 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors treatment 2 completed NCT00004074 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu treatment 1 completed NCT01525082 Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors treatment 2 completed NCT00001191 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid treatment 2 completed NCT04915144 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs treatment 2 withdrawn